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Implication for health policy/practice/research/medical education:
Zolpidem is a nonspecific hypnotic drug that has antioxidant and neuroprotective properties. Cisplatin is mainly secreted through 
the kidneys, and its accumulation in tubular tuberculosis is more than 5 times greater than other tissues. Zolpidem exhibits this 
effect by reducing oxidative stress, increasing the activity of the antioxidant system, including superoxide dismutase (SOD), 
catalase (CAT) and glutathione peroxidase (GPX), and preventing apoptosis in renal cells. The present study has approved, the 
antioxidant effect of zolpidem on the improvement of the defect of antioxidant system of the kidney in nephrotoxicity.
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Introduction: Nephrotoxicity is one of the most important side effects of cisplatin which has 
limited its use. Production of reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) plays a significant role in the pathogenesis of this drug. 
Objectives: The aim of this study was to evaluate the antioxidant effect of zolpidem on the 
reduction of nephrotoxicity associated with cisplatin.
Materials and Methods: In this study, 40 adult male rats were divided into 4 groups; 1) 
healthy group, 2) control group, 3, 4) cisplatin-induced nephrotoxicity + different doses of 
zolpidem. After a certain period of time, the urine, spinal cord and kidney samples of rats were 
collected. Then, urine levels of functional factors including urea, creatinine and albumin/
creatinine ratio, antioxidant enzymes and malondialdehyde (MDA) levels were estimated. 
Consequently, histological studies were conducted with the collected samples. 
Results: Zolpidem reduced levels of urea, creatinine, albumin/creatinine ratio, and MDA. 
It also increased the amount of antioxidant enzymes of the kidney including superoxide 
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX), and moderated the 
tubular damage caused by the use of cisplatin.
Conclusion: Zolpidem is able to improve the nephrotoxicity by reducing oxidative stress.
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The cisplatin alkylating agent is one of the most widely 
used chemotherapy drugs for treating a variety of 
cancers including lung, testicular, ovarian, breast, head, 
neck and bladder (1,2). This drug stops the replication 
and transcription of the genetic material and ultimately 
inhibits the growth and proliferation of cancer cells by 
binding to DNA and proteins (1,3,4). It also increases the 
oxidative stress by stimulating the production of reactive 
oxygen species (ROS) and reactive nitrogen species 
(RNS), causing damage to subcellular structures and 
macromolecules such as DNA, proteins and lipids (5,6). 
Cisplatin is mainly secreted through the kidneys, and its 
accumulation in tubular tuberculosis is more than 5 times 
greater than other tissues (7,8). Previous studies have 
indicated that the clinical use of cisplatin in 25%-35% of 
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hospitalized patients undergoing chemotherapy leads to 
nephrotoxicity, which limits the dose and duration of use 
of the drug (9). In many studies, the mechanism of the 
occurrence of this complication includes the induction 
of free radicals’ generation, oxidative damage, and lipid 
peroxidation in the kidney (10-12). Therefore, researchers 
have evaluated the role of antioxidant agents in improving 
renal injury caused by cisplatin. Zolpidem is a nonspecific 
hypnotic drug that has antioxidant and neuroprotective 
properties (13). Studies have shown that zolpidem and 
its derivatives can trap free radicals, and reduce lipid 
peroxidation, protein oxidation and carbonyl formation 
(14). Nonetheless, its effect on kidney tissues has not been 
studied yet. 
Objectives
In the present study, the antioxidant role of this substance 
in the improvement of cisplatin nephrotoxicity will be 
investigated.
Materials and Methods
This experimental study was performed on 40 adult male 
rats weighing 250-230 g purchased from Razi Herbal 
Medicines Research Center, Lorestan, Iran. Water and 
food were provided freely, and the rats were kept at a 
12-hour light and 12-hour dark cycle at an appropriate 
temperature. Animals were randomly divided into four 
groups of ten rats before each experiment as follows;
Group 1: healthy group which did not receive any 
medication.
Group 2: control group which received cisplatin (2.5 mg/
kg) daily for intraperitoneal injection for 3 weeks for the 
purpose of the induction of nephrotoxicity.
Group 3: nephrotoxicity group treated with zolpidem (2 
mg/kg) for 11 days from the 10th day.
Group 4: nephrotoxicity group treated with zolpidem (4 
mg/kg) for 11 days from the 10th day.
Evaluation of the renal structure and level of oxidative 
stress factors
In order to evaluate the renal structure and the level of 
oxidative stress factors such as superoxide dismutase 
(SOD), catalase (CAT) and glutathione peroxidase 
(GPX) Malondialdehyde (MDA) on the last day (21st 
day), the first urine samples were prepared and the levels 
of creatinine, urea and the ratio of albumin to urine 
creatinine were measured by the use of commercial kits 
(prepared by Diasis Diagnostic System Istanbul/Turkey). 
Following the collection of urine samples, we anesthetized 
the animals using pentobarbital, and then, dorsal area of 
rats and subsequently the muscles were separated from the 
spinal column and finally the spinal column was removed 
completely. Then, the spinal cord was completely removed 
using distilled water injection into the spinal canal. After 
separating the spinal cord, it was lysed with buffer (Tris 
HCl, pH 7.5 Sucrose, 0.01 M 5 mM MgCl2, 1% Triton 
X100 0.3M) and eventually the supernatant was isolated 
in order to evaluate the oxidative stress level with ELISA 
kits (Sigma Aldrich, USA).
Kidney histology
After urine collection and spinal separation on the last day, 
the left kidneys were removed in order to evaluate kidney 
tissue. Subsequently, the paraffin blocks of samples were 
prepared and cut using a micrometer with a thickness 
of 3 µm. The samples were stained with H&E staining 
and then the severity of tissue necrosis and degeneration 
of the epithelial cells of the kidneys were assessed 
microscopically. (No damage = 0, mild = 1; unicellular 
patchy isolated, moderate = 2; damage less than 25%, 
severe = 3; damage between 25%-50%, very severe = 4; 
more than 50% damage).
Ethical issues
The research followed the tenets of the Declaration 
of Helsinki. The protocol of this study is designed 
in accordance with the ethical principles of the 
International Committees for the Protection of Animal 
Rights Laboratory. This project was approved by Ethics 
Committee of Lorestan University of Medical Sciences. 
Statistical analysis
Appropriate central and diffusion indices were calculated 
for data analysis using one-way ANOVA or Kruskal-Wallis 
test. SPSS version 16 was also used for data analysis. The 
significance level was considered as P < 0.05. Hormonal 
and enzymatic data were analyzed using GraphPad 
software and one-way ANOVA data.
Results
Effect of zolpidem on functional and structural 
parameters of the kidneys
According to our results, cisplatin administration causes 
impaired kidney function. This dysfunction was evaluated 
by measuring urine levels of urea, creatinine, and albumin/
creatinine.
In all three cases, there was a significant increase in 
their levels in group 2 (control) compared to group 1 
(P < 0.05) (Figure 1A-C), in which the amount of albumin/ 
creatinine ratio was doubled. The intraperitoneal injection 
of zolpidem to groups 3 and 4 resulted in a significant 
decrease in the values of functional parameters of the 
kidneys, in a dose-dependent manner, which means that 
with an increase in the injectable dose of zolpidem in 
group 4 in comparison with group 3, the level of urea, 
creatinine and albumin/creatinine ratio significantly 
decreased. The chart shows a slower rate of decrease in 
albumin/creatinine ratio evaluation compared to urea and 
creatinine.
Effect of zolpidem on oxidative stress and anti-oxidant 
system deficiency by cisplatin
Our results indicated that cisplatin significantly reduced 
the antioxidant enzymes of the kidney, including GPx, 
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SOD and CAT in group 2, and at the same time remarkably 
increased the MDA (oxidative stress marker). The 
administration of zolpidem in dose-dependent manner 
led to a significant increase in antioxidant enzymes in 
groups 3 and 4 (P < 0.05) (Figure 1D-G). Furthermore, 
a comparing between the amount of MDA in groups 
2 and 4 indicated that zolpidem could reduce the lipid 
peroxidation induced by cisplatin by half.
Effect of zolpidem on cisplatin-induced kidney tissue 
damage
Cisplatin causes apoptotic and necrotic death in kidney 
tubular cells. We clearly observed the cisplatin-induced 
renal injury in H&E stained tissue sections. Under the 
influence of zolpidem, this damage was reduced. Moreover, 
tubular death, necrosis and renal cell degeneration 
significantly decreased.
Discussion 
The most important side effect of dose-dependent 
administration of cisplatin is nephrotoxicity (2). This 
drug has been associated with the induction of multiple 
signaling factors and pathways, including one of the 
most important mechanisms for stimulating oxidative 
Figure 1. The effects of zolpidem on the level of (A) urea, (B) creatinine, (C) albumin/creatinine ratio, (D) GPx, (E) SOD, (F) CAT and 
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stress, reducing or malfunctioning of antioxidant agents, 
and increasing the production of free radicals (9,12,15). 
Following these disorders, apoptosis and necrosis of the 
tubular cells will occur (16-18), which will, in turn, change 
various parameters of the kidney including urea, creatinine, 
MDA, CAT, GPx, and SOD (19-22). We also observed 
urine level changes of these parameters in group 2. To 
date, the only strategy used to limit nephrotoxicity is the 
hydration of patients during the course of treatment (23). 
However, some complications are relatively irreversible, 
and defects in tubular renewal capacity can lead to the 
onset and spread of kidney fibrosis (16). Hence, there is 
an urgent need to develop methods to prevent or treat this 
complication. Cisplatin, by binding to the mitochondrial 
DNA and causing impairment in its transcription, reduces 
the synthesis of proteins and subsequently reduces the 
components of the electron transport chain. Consequently, 
oxidative phosphorylation has a defect that ultimately 
stimulates ROS production (24). Nephrotoxicity caused 
by cisplatin is induced by oxidative stress (25). Many 
studies, including the present research, have indicated 
the oxidative damage and production of free radicals 
in the kidney brought about by cisplatin (10,11). These 
factors can alter the structure of cellular macromolecules, 
including DNA, proteins and lipids, and can also lead to 
cell death (16). Regarding the mechanisms of cisplatin in 
the development of nephrotoxicity, several studies have 
investigated the role of various bioactive compounds with 
antioxidant properties in protecting the kidneys against the 
damage caused by oxidative cisplatin effects. Substances 
with antioxidant properties, such as daidzein in soybeans 
(3), fisetin (2), green tea (26), honey (27), ferulic acid (1), 
ellagic acid (19) and other antioxidants, have increased 
the levels of antioxidant system of the kidney tissues that 
greatly reduces nephrotoxicity. The results of this study 
confirmed a significant positive effect of zolpidem on the 
improvement of renal damage caused by cisplatin. The 
zolpidem imitates its antioxidant property by having a 
structure similar to melatonin (13,14). According to our 
results, zolpidem exhibits this effect by reducing oxidative 
stress, increasing the activity of the antioxidant system, 
including SOD, CAT and GPx, and preventing apoptosis 
in renal cells. This feature was confirmed by measuring 
the amount of MDA in tissue in 2004, which indicated 
the inhibitory effect of zolpidem on the induction of lipid 
peroxidation in the liver and brain of rats (13). 
Conclusion
The present study has approved, for the first time, the 
antioxidant effect of zolpidem on the improvement 
of the defect of antioxidant system of the kidney in 
nephrotoxicity. Based on the results, pre-treatment with 
zolpidem causes the balance of the oxidant/antioxidant 
system to improve the function of the tubular cells of the 
kidneys. Hence, there will occur the adjusting of the urine 
level of its functional indices. Adjustment of the balance of 
the production of ROS and antioxidant defense enzymes is 
essential in order to control or reduce the nephrotoxicity 
caused by cisplatin. Further studies are recommended to 
explore other mechanisms involved in the improvement 
process and how they are induced by zolpidem.
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